GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier

Biotechnology and Bioengineering

Volumn 100, Issue 2, 2008, Pages 387-396

  Boado, Ruben J ^a,b   Zhang, Yun ^a,b   Zhang, Yufeng ^a   Wang, Yuntao ^b   Pardridge, William M ^b  

^a ArmaGen Technologies Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Drug targeting; Neurotrophin; Parkinson's disease; Stroke

Indexed keywords

BLOOD; DISEASE CONTROL; DRUG DELIVERY; GENE EXPRESSION;

BLOOD BRAIN BARRIER; DRUG TARGETING; GLIAL-DERIVED NEUROTROPHIC FACTOR (GDNF);

PROTEINS;

GLIAL DERIVED NEUROTROPHIC FACTOR; HYBRID PROTEIN; INSULIN RECEPTOR; LUCIFERASE; MONOCLONAL ANTIBODY; NEUROTROPHIC FACTOR; PROTEIN RET; TYROSINE 3 MONOOXYGENASE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING ASSAY; BLOOD BRAIN BARRIER; CARBOXY TERMINAL SEQUENCE; CELL STRAIN COS1; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC TRANSFECTION; HEART STROKE VOLUME; HEAVY CHAIN; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LIGHT CHAIN; NERVE CELL; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PLASMID; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; REPORTER GENE; STATISTICAL SIGNIFICANCE;

ANIMALS; BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEMS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INFARCTION, MIDDLE CEREBRAL ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

RATTUS;

EID: 44449128659     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21764     Document Type: Article

References (26)

1. Boado RJ, Zhang Y, Zhang Y, Pardridge WM. 2007a. Humanization of antihuman insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng 96:381-391.
2. Boado RJ, Zhang Y, Zhang Y, Pardridge WM. 2007b. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol Bioeng 97:1376-1386.
3. Boado RJ, Zhang Y, Zhang Y, Xia CF, Pardridge WM. 2007c. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem 18:447-455.
4. Boado RJ, Zhang Y, Zhang Y, Xia CF, Wang Y, Pardridge WM. 2008. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng 99:475-484.
5. Bohn MC. 2004. Motoneurons crave glial cell line-derived neurotrophic factor. Exp Neurol 190:263-275.
6. Qk M, Masure S, Lesage AS, Van Der Linden I, Van Gompel P, Pangalos MN, Gordon RD, Leysen JE. 2000. Binding of GDNF and neurturin to human GDNF family receptor alpha 1 and 2. Influence of cRET and cooperative interactions. J Biol Chem 275:27505-27512.
7. Coloma MJ, Lee HJ, Kurihara A, Landaw EM, Boado RJ, Morrison SL, Pardridge WM. 2000. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res 17:266-274.
8. Eketjall S, Fainzilber M, Murray-Rust J, Ibanez CF. 1999. Distinct structural elements in GDNF mediate binding to GFRalphal and activation of the GFRalpha1-c-Ret receptor complex. EMBO J 18:5901-5910.
9. Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Annett L, Kirik D. 2005. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 25:769-777.
10. Hirata Y, Kiuchi K. 2003. Mitogenic effect of glial cell line-derived neurotrophic factor is dependent on the activation of p70S6 kinase, but independent of the activation of ERK and up-regulation of Ret in SH-SY5Y cells. Brain Res 983:1-12.
11. Kastin AJ, Akerstrom V, Pan W. 2003. Glial cell line-derived neurotrophic factor does not enter normal mouse brain. Neurosci Lett 340:239-241.
12. Kitagawa H, Hayashi T, Mitsumoto Y, Koga N, Itoyama Y, Abe K. 1998. Reduction of ischemic brain injury by topical application of glial cell line-derived neurotrophic factor after permanent middle cerebral artery occlusion in rats. Stroke 29:1417-1422.
13. Kobayashi T, Ahlenius H, Thored P, Kobayashi R, Kokaia Z, Lindvall O. 2006. Intracerebral infusion of glial cell line-derived neurotrophic factor promotes striatal neurogenesis after stroke in adult rats. Stroke 37:2361-2367.
14. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, Stacy M, Turner D, Wooten VGF, Elias WJ, Laws ER, Dhawan V, Stoessl AJ, Matcham J, Coffey RJ, Traub M. 2006. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59:459-466.
15. Lapchak PA, Miller PJ, Collins F, Jiao S. 1997. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: Comparison of intraventricular and intranigral delivery. Neuroscience 78:61-72.
16. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. 1993. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132.
17. Pardridge WM. 2007. Drug targeting to the brain. Pharm Res 24:1733-1744.
18. Pardridge WM, Kang YS, Buciak JL, Yang J. 1995. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res 12:807-816.
19. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS. 2005. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study. Ann Neurol 57:298-302.
20. Sullivan AM, Opacka-Juffy J, Blunt SB. 1998. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo. Eur J Neurosci 10:57-63.
21. Tanaka M, Xiao H, Hirata Y, Kiuchi K. 2003. A rapid assay for glial cell line-derived neurotrophic factor and neurturin based on transfection of cells with tyrosine hydroxylase promoter-luciferase construct. Brain Res Brain Res Protoc 11:119-122.
22. Wiesenhofer B, Stockhammer G, Kostron H, Maier H, Hinterhuber H, Humpel C. 2000. Glial cell line-derived neurotrophic factor (GDNF) and its receptor (GFR-alpha 1) are strongly expressed in human gliomas. Acta Neuropathol (Berl) 99:131-137.
23. Xiao H, Hirata Y, Isobe K, Kiuchi K. 2002. Glial cell line-derived neurotrophic factor up-regulates the expression of tyrosine hydroxylase gene in human neuroblastoma cell lines. J Neurochem 82:801-808.
24. Xu RY, Pong K, Yu Y, Chang D, Liu S, Lile JD, Treanor J, Beck KD, Louis JC. 1998. Characterization of two distinct monoclonal antibodies specific for glial cell line-derived neurotrophic factor. J Neurochem 70:1383-1393.
25. Zhang Y, Pardridge WM. 2001a. Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res 889:49-56.
26. Zhang Y, Pardridge WM. 2001b. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke 32:1378-1384.